HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kjell Matthias Kaune Selected Research

Nivolumab

5/2023Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kjell Matthias Kaune Research Topics

Disease

1Melanoma (Melanoma, Malignant)
05/2023
1Skin Neoplasms (Skin Cancer)
05/2023
1Obesity
10/2016
1Alcoholism (Alcohol Abuse)
10/2016
1Hypertension (High Blood Pressure)
10/2016
1Leukemia
10/2009
1Neoplasms (Cancer)
10/2009
1Pneumonia (Pneumonitis)
03/2008
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2008
1Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
03/2008
1B-Cell Lymphoma (Lymphoma, B Cell)
07/2007
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/2007
1Lymphoma (Lymphomas)
07/2007

Drug/Important Bio-Agent (IBA)

1pembrolizumabIBA
05/2023
1NivolumabIBA
05/2023
1AntibodiesIBA
05/2023
1NicotineFDA Link
10/2016
1nilotinibFDA Link
03/2008
1Tyrosine Kinase InhibitorsIBA
03/2008

Therapy/Procedure

2Drug Therapy (Chemotherapy)
10/2009 - 07/2007
1Therapeutics
05/2023